688062 迈威生物-U
已收盘 06-12 15:00:00
资讯
新帖
简况
迈威生物-U（688062）6MW5311临床试验申请获国家药监局受理审评
美股速递 · 06-12 19:32
迈威生物-U（688062）6MW5311临床试验申请获国家药监局受理审评
迈威生物-U获美国FDA批准开展临床试验
美股速递 · 06-12 19:32
迈威生物-U获美国FDA批准开展临床试验
迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可
智通财经 · 06-12 16:25
迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可
每周股票复盘：迈威生物（688062）召开两次临时股东会
证券之星 · 06-07
每周股票复盘：迈威生物（688062）召开两次临时股东会
迈威生物-U 9MW5211注射液临床试验申请获国家药监局批准
投资观察 · 06-04
迈威生物-U 9MW5211注射液临床试验申请获国家药监局批准
迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准
美股速递 · 06-04
迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准
智通财经 · 06-04
迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准
从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进
格隆汇 · 06-03
从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进
迈威生物（688062）披露关于申请注册发行定向债务融资工具的议案获通过，6月2日股价下跌1.62%
证券之星 · 06-02
迈威生物（688062）披露关于申请注册发行定向债务融资工具的议案获通过，6月2日股价下跌1.62%
股市必读：迈威生物（688062）今年截至6月1日累计跌幅已超25%
证券之星 · 06-02
股市必读：迈威生物（688062）今年截至6月1日累计跌幅已超25%
股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%
证券之星 · 05-29
股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%
每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%
证券之星 · 05-24
每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%
迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%
证券之星 · 05-21
迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%
迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据
智通财经网 · 05-21
迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据
迈威生物宣布：迈卫健®注射液新增适应症补充申请获国家药监局批准
美股速递 · 05-20
迈威生物宣布：迈卫健®注射液新增适应症补充申请获国家药监局批准
迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准
智通财经 · 05-20
迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准
5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股
证券之星 · 05-11
5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股
港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可
智通财经网 · 05-11
港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可
迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准
美股速递 · 05-08
迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可
智通财经网 · 05-08
迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":28.53,"timestamp":1781247600000,"preClose":27.23,"halted":0,"volume":10894424,"delay":0,"changeRate":0.0477,"floatShares":204000000,"shares":447000000,"eps":-2.0584,"marketStatus":"已收盘","change":1.3,"latestTime":"06-12 15:00:00","open":27.3,"high":28.98,"low":26.87,"amount":306000000,"amplitude":0.0775,"askPrice":28.53,"askSize":16,"bidPrice":28.52,"bidSize":13,"shortable":0,"etf":0,"ttmEps":-2.0584,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":27.23,"symbolType":"stock_kcb","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":29.95,"lowLimit":24.51,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446730200,"isCdr":false,"pbRate":119.32,"roa":"--","roe":"--","epsLYR":-2.43,"committee":-0.538462,"marketValue":12745000000,"turnoverRate":0.0534,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-15。","afterMarket":{"amount":0,"volume":0,"close":28.53,"buyVolume":0,"sellVolume":0,"time":1781249638866,"indexStatus":"已收盘 06-12 15:30:00","preClose":27.23},"hkstockBrief":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":25.1,"timestamp":1781251699617,"preClose":25.56,"halted":0,"volume":2588400,"delay":0,"premium":"-24.06"},"floatMarketCap":5825000000},"requestUrl":"/m/hq/s/688062/","defaultTab":"news","newsList":[{"id":"1171719233","title":"迈威生物-U（688062）6MW5311临床试验申请获国家药监局受理审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1171719233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171719233?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:32","pubTimestamp":1781263938,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其新药6MW5311的临床试验申请已正式获得国家药品监督管理局的受理，并进入审评阶段。这一进展标志着该候选药物的研发进程向前迈出了关键一步，为后续的临床研究奠定了重要的监管基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186538649","title":"迈威生物-U获美国FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1186538649","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186538649?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:32","pubTimestamp":1781263935,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其已收到美国食品药品监督管理局（FDA）签发的临床试验可以进行通知。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026565","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642026565?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:25","pubTimestamp":1781252747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。6MW5311为全球首款获批开展临床试验的靶向LILRB4/CD3的TCE创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK0239","BK4588","688062","BK1161","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127863","title":"每周股票复盘：迈威生物（688062）召开两次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127863?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:58","pubTimestamp":1780768691,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，迈威生物报收于26.6元，较上周的30.4元下跌12.5%。本周，迈威生物6月1日盘中最高价报31.44元。本周关注点来自公司公告汇总：迈威生物召开2026年第二次临时股东会，审议通过申请注册发行定向债务融资工具的议案。公司公告汇总迈威（上海）生物科技股份有限公司于2026年6月1日召开2026年第二次临时股东会，会议由董事会召集，董事长刘大涛主持，采用现场与网络投票结合方式召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109189720","title":"迈威生物-U 9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1109189720","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109189720?lang=zh_cn&edition=full","pubTime":"2026-06-04 23:43","pubTimestamp":1780587826,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司（股票代码：688062.SS）宣布，其9MW5211注射液的临床试验申请已获得中国国家药品监督管理局（NMPA）的批准。\n这一进展标志着该公司在研产品管线取得了重要一步，为后续的临床开发铺平了道路。市场对此消息反应积极，关注该产品未来的研发进程及其潜在的市场前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122857975","title":"迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1122857975","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122857975?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:12","pubTimestamp":1780578745,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其9MW5211注射液的临床试验申请已获得中国国家药品监督管理局的正式批准。\n公司致力于创新生物药的研发，此次获批标志着其研发管线取得重要进展。9MW5211是一款在研药物，此次获批将推动其进入下一阶段的临床研究，以评估其在目标适应症中的安全性与有效性。\n这一监管进展为公司的长远发展注入了新的动力，也体现了其在生物医药领域的持续创新能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615959","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640615959?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:05","pubTimestamp":1780567515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于炎症性肠病适应症的临床试验申请获得批准，此外，其用于IBD适应症的美国临床试验申请已获得FDA许可，用于多发性硬化等多个适应症的临床试验申请获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640897041","title":"从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进","url":"https://stock-news.laohu8.com/highlight/detail?id=2640897041","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640897041?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:20","pubTimestamp":1780478447,"startTime":"0","endTime":"0","summary":"从ASCO上的亮眼数据，到ESMO GC即将揭晓的宫颈癌数据，再到迈卫健的适应症“扩围”:迈威生物在短时间内打出了一套漂亮的“组合拳”。","market":"sg","thumbnail":"https://img2.gelonghui.com/d273d-c22ea71a-0f20-4fd3-9fb7-a14ae8e7ce94.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-c22ea71a-0f20-4fd3-9fb7-a14ae8e7ce94.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5047096","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","BK0239","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640391139","title":"迈威生物（688062）披露关于申请注册发行定向债务融资工具的议案获通过，6月2日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640391139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640391139?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:42","pubTimestamp":1780393357,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，迈威生物报收于28.51元，较前一交易日下跌1.62%，最新总市值为127.36亿元。该股当日开盘28.88元，最高29.26元，最低27.71元，成交额达2.16亿元，换手率为3.73%。公告显示，公司于2026年6月1日召开2026年第二次临时股东会，审议通过《关于申请注册发行定向债务融资工具的议案》。该议案为普通决议议案，已获出席股东所持表决权过半数通过。出席会议股东共131人，代表有表决权股份201,449,250股，占公司总表决权股份的45.2148%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640966924","title":"股市必读：迈威生物（688062）今年截至6月1日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640966924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640966924?lang=zh_cn&edition=full","pubTime":"2026-06-02 01:38","pubTimestamp":1780335489,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，迈威生物报收于28.98元，下跌4.67%，换手率4.5%，成交量9.18万手，成交额2.74亿元。当日关注点来自交易信息汇总：迈威生物股价报28.98元，跌4.67%，已连续5日下跌，年内累计跌幅达25.41%。来自公司公告汇总：迈威生物召开2026年第二次临时股东会，审议通过申请注册发行定向债务融资工具的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639690317","title":"股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639690317?lang=zh_cn&edition=full","pubTime":"2026-05-29 01:00","pubTimestamp":1779987637,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，迈威生物报收于30.59元，下跌4.73%，换手率3.82%，成交量7.79万手，成交额2.42亿元。当日关注点来自交易信息汇总：迈威生物股价连续3日下跌，当日主力资金净流出3344.38万元，占总成交额13.82%。交易信息汇总股价提醒5月28日迈威生物收盘报30.59元，跌4.73%，当日成交779.41万元。该股已连续3日下跌，当年累计跌幅21.26%。前10个交易日主力资金累计净流出5861.72万元，股价累计下跌13.61%；融资余额累计增加852.75万元，融券余量累计增加1.71万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637782093","title":"每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637782093","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637782093?lang=zh_cn&edition=full","pubTime":"2026-05-24 01:48","pubTimestamp":1779558494,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，迈威生物报收于33.31元，较上周的34.34元下跌3.0%。本周，迈威生物5月22日盘中最高价报35.35元。公司公告汇总：9MW2821联合特瑞普利单抗在尿路上皮癌中整体人群ORR达83.0%。迈威生物自主研发的靶向Nectin-4 ADC药物9MW2821在2026年ASCO年会上以口头报告和壁报形式展示最新临床数据。9MW2821联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II期研究显示，整体人群客观缓解率为83.0%，经确认ORR为74.5%，完全缓解率12.8%，中位无进展生存期12.9个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637051332","title":"迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637051332","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637051332?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:38","pubTimestamp":1779374294,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，迈威生物报收于33.48元，较前一交易日上涨1.09%，最新总市值为149.57亿元。该股当日开盘33.25元，最高35.07元，最低33.25元，成交额达3.61亿元，换手率为5.18%。近日，迈威生物发布自愿披露公告，宣布其自主研发的靶向Nectin-4 ADC药物9MW2821在2026年美国临床肿瘤学会年会上，将以口头报告和壁报形式展示最新临床数据。两项研究均未发现新的安全性信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637389898","title":"迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637389898","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637389898?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:17","pubTimestamp":1779355058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司将在2026年5月29日-6 月2日于芝加哥举行的2026年美国临床肿瘤学会年会中，以口头报告形式公布靶向Nectin-4ADC创新药9MW2821 联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II 期临床研究数据，以壁报形式公布9MW2821联合特瑞普利单抗用于围手术期肌层浸润性膀胱癌的II期临床研究数据。9MW2821给药后，可与肿瘤细胞表面的Nectin-4结合并进入细胞，通过酶解作用，定向释放细胞毒素，从而实现对肿瘤的精准杀伤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163729672","title":"迈威生物宣布：迈卫健®注射液新增适应症补充申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1163729672","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163729672?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:46","pubTimestamp":1779288374,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司宣布，其核心产品迈卫健®注射液新增适应症补充申请，已正式获得国家药品监督管理局的批准。\n此次获批意味着迈卫健®注射液的临床应用范围得到进一步拓宽，将为更广泛的适应症患者群体提供新的治疗选择。作为公司重要的在研及商业化产品，此次监管进展有望强化其市场地位，并为未来的商业化表现注入新的增长动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636121668","title":"迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636121668","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636121668?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:27","pubTimestamp":1779265627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司全资子公司江苏泰康生物医药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，地舒单抗注射液增加实体肿瘤骨转移和多发性骨髓瘤适应症的补充申请获得国家药品监督管理局批准。公告显示，迈卫健主要竞争优势在于：1)作为国内第一梯队上市的安加维生物类似药，先发优势明显;2)展现了良好的治疗效果，被多个专家共识或治疗指南推荐。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409827","title":"5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409827?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488118,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日迈威生物涨5.80%，收盘报37.2元，换手率6.99%，成交量14.28万手，成交额5.18亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.7862，较上一交易日下跌2.29%，近一年上涨13.89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","000808.SH","BK1161","163118","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634472914","title":"港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2634472914","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634472914?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:57","pubTimestamp":1778479078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B午后涨近5%，截至发稿，涨3.54%，报27.52港元，成交额3326.31万港元。消息面上，迈威生物宣布，其自主研发的抗体创新药9MW5211的临床试验申请正式获得美国食品药品监督管理局的许可，可针对炎症性肠病开展临床研究。其用于IBD和多发性硬化等多个适应症的临床试验申请已获国家药品监督管理局受理。9MW5211在其靶点上是全球首款进入临床阶段的候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","159992","VXUS","02493","688062","LABU","06978","BK4585","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154828404","title":"迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1154828404","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154828404?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:55","pubTimestamp":1778252116,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其研发的9MW5211注射液用于治疗炎症性肠病的临床试验申请，已获得美国食品药品监督管理局（FDA）的正式批准。这一进展标志着该药物在海外临床开发方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432532","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432532","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432532?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:15","pubTimestamp":1778235339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，，9MW5211注射液用于炎症性肠病适应症的临床试验申请正式获得FDA许可，同时，其用于IBD和多发性硬化等多个适应症的临床试验申请已获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK4585","BK4588","688062","BK1161","02493","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781427383252,"stockEarnings":[{"period":"1week","weight":0.0726},{"period":"1month","weight":-0.1895},{"period":"3month","weight":-0.1383},{"period":"6month","weight":-0.3007},{"period":"1year","weight":-0.0352},{"period":"ytd","weight":-0.2584}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18977人(较上一季度增加2.21%)","perCapita":"10758股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"44673万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-U,688062,迈威生物-U股票,迈威生物-U股票老虎,迈威生物-U股票老虎国际,迈威生物-U行情,迈威生物-U股票行情,迈威生物-U股价,迈威生物-U股市,迈威生物-U股票价格,迈威生物-U股票交易,迈威生物-U股票购买,迈威生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}